MedTrace Logo

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

NCT04892446 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-05-02

Study results available
· View outcomes & findings →

Summary

The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.

Conditions

Interventions

DRUG

Magrolimab

Administered IV

DRUG

Daratumumab

Administered either SC or IV

DRUG

Pomalidomide

Administered orally

DRUG

Dexamethasone

Administered orally

DRUG

Bortezomib

Administered either SC or IV

DRUG

Carfilzomib

Administered IV

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-09
Primary Completion
2024-04-25
Completion
2024-04-25
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Czechia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04892446 on ClinicalTrials.gov